Hotta Osamu
Department of Nephropathy, Sendai Shakaihoken Hospital, Sendai, Japan.
Adv Otorhinolaryngol. 2011;72:37-9. doi: 10.1159/000324592. Epub 2011 Aug 18.
IgA nephropathy (IgAN), the most common form of primary glomerulonephritis progressing to end-stage renal disease (ESRD), has been regarded as an incurable disease. However, in recent years, it has been demonstrated that combined tonsillectomy with steroid pulse (TS) therapy, if administrated in the relatively early stage of the disease, can yield clinical remission in patients with IgAN. However, clinical remission is no longer obtained when the same treatment is administrated in cases with more advanced disease and/or a longer duration of nephropathy. Thus, the paradigm of managing IgAN patients is shifting in Japan from 'slowing the progression and the delaying the onset of ESRD' (by conventional therapy using a RAS inhibitor and/or corticosteroids at low doses in selected patients with advanced IgAN) to 'achieving remission' by the TS therapy in patients with early disease. In the new paradigm aimed at clinical remission, the principle for initiation of TS therapy should be 'the earlier, the better'.
IgA肾病(IgAN)是进展为终末期肾病(ESRD)的最常见的原发性肾小球肾炎形式,一直被视为一种无法治愈的疾病。然而,近年来已证明,在疾病相对早期进行扁桃体切除术联合类固醇脉冲(TS)治疗,可使IgA肾病患者实现临床缓解。然而,在疾病更晚期和/或肾病病程更长的病例中采用相同治疗时,不再能获得临床缓解。因此,日本管理IgA肾病患者的模式正在从“减缓进展并延迟ESRD的发生”(通过在选定的晚期IgA肾病患者中使用RAS抑制剂和/或低剂量皮质类固醇进行传统治疗)转变为通过TS治疗使早期疾病患者“实现缓解”。在旨在实现临床缓解的新模式中,启动TS治疗的原则应为“越早越好”。